CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors.
Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
将嵌合抗原受体(CAR)T细胞应用于实体瘤,需要提高其疗效和安全性。缺氧是多数实体瘤的特征,可用于帮助CAR-T 区分肿瘤与正常组织。本研究通过将CAR置于缺氧应答元件调控之下,开发缺氧响应型CAR-T,并筛选出最佳结构5H1P-CEA CAR;该CAR可在肿瘤缺氧微环境中激活,诱导CAR-T 细胞表现出高度多功能性。在常氧条件下,缺氧响应型CAR-T 处于“静息”状态,CAR表达较低。与传统CAR-T 相比,缺氧响应型CAR-T 培养期间保持较低分化状态,氧化代谢和增殖能力更强,并能减轻缺氧对T细胞增殖和代谢的负面影响。此外,5H1P-CEA CAR-T 体内T细胞耗竭较少,表型改善。在患者来源异种移植模型中,其抗肿瘤活性较传统CAR-T 更持久。总之,本研究提出一种将CAR表达限制于缺氧肿瘤微环境的方法,有望增强CAR-T 治疗实体瘤的疗效和安全性。意义:工程化CAR-T 使其在缺氧条件下上调CAR表达,可诱导代谢重编程、减少分化并提高增殖,从而增强抗肿瘤活性,为改善疗效与安全性提供策略。
UNLABELLED: Expanding the utility of chimeric antigen receptor (CAR)-T cells in solid tumors requires improving their efficacy and safety. Hypoxia is a feature of most solid tumors that could be used to help CAR-T cells discriminate tumors from normal tissues. In this study, we developed hypoxia-responsive CAR-T cells by engineering the CAR to be under regulation of hypoxia-responsive elements and selected the optimal structure (5H1P-CEA CAR), which can be activated in the tumor hypoxic microenvironment to induce CAR-T cells with high polyfunctionality.
Hypoxia-responsive CAR T cells were in a "resting" state with low CAR expression under normoxic conditions. Compared with conventional CAR-T cells, hypoxia-responsive CAR-T cells maintained lower differentiation and displayed enhanced oxidative metabolism and proliferation during cultivation, and they sowed a capacity to alleviate the negative effects of hypoxia on T-cell proliferation and metabolism.
Furthermore, 5H1P-CEA CAR-T cells exhibited decreased T-cell exhaustion and improved T-cell phenotype in vivo. In patient-derived xenograft models, hypoxia-responsive CAR-T cells induced more durable antitumor activity than their conventional counterparts.
Overall, this study provides an approach to limit CAR expression to the hypoxic tumor microenvironment that could help to enhance CAR T-cell efficacy and safety in solid tumors. SIGNIFICANCE: Engineering CAR-T cells to upregulate CAR expression under hypoxic conditions induces metabolic reprogramming, reduces differentiation, and increases proliferation to enhance their antitumor activity, providing a strategy to improve efficacy and safety.
MEMBER ACCOUNT
登录成功会直接打开下一页。